Sionna Therapeutics, Inc.
SION- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002036042
In the last 90 days, Sionna Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 146 institutions reported holding it in 13F filings for Q2 2026, worth $2.11B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2025 vs. Q1 2025
How the institutions holding Sionna Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 47 | 65 | +18 |
| Shares | 41.5M | 43.4M | +1.96M (+4.7%) |
| Value | $434.1M | $753.8M | +$319.8M (+73.7%) |
New holders (26)
Institutions that held Sionna Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (8)
Institutions that held Sionna Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Zimmer Partners, LP | 237,500 | $2.48M |
| CenterBook Partners LP | 114,284 | $1.20M |
| StemPoint Capital LP | 60,000 | $627.6K |
| Squarepoint Ops LLC | 33,964 | $355.3K |
| Aster Capital Management (DIFC) Ltd | 14,757 | $203.2K |
| Balyasny Asset Management LLC | 13,060 | $136.6K |
| Marshall Wace, LLP | 12,188 | $127.5K |
| Two Sigma Investments, LP | 11,715 | $122.5K |